Hayward CA. -Kosan Biosciences, Inc. announced today that Susan M. Kanaya has joined the company as Vice President, Finance and Chief Financial Officer.
« Susan brings more than fifteen years of experience in financial planning and management to Kosan, » said Michael S. Ostrach, Chief Operating Officer. « Her expertise will be extremely valuable as Kosan continues its development from a development stage company into an operating company. »
Prior to joining Kosan, Ms. Kanaya was Vice President, Finance at SUGEN, Inc., a publicly-held biotechnology company that recently became a subsidiary of Pharmacia & Upjohn. Since joining SUGEN in 1994 Ms. Kanaya held various positions in Finance and was responsible for financial planning and analysis, financial reporting, corporate financings and treasury and risk management.
Before joining SUGEN, Ms. Kanaya was the Controller at 50/50 Micro Electronics, Inc. and at Power Up Software Corporation. She also held financial analyst and accounting positions at American President Lines, Ltd., Wells Fargo Bank and KPMG Peat Marwick.
Ms. Kanaya graduated from the University of California, Berkeley with a BS in Business Administration, with an emphasis on Accounting and Finance.
Kosan Biosciences, Inc. is a privately held biotechnology company focused on generating small molecule compounds by genetic engineering of biosynthetic pathways, with an initial focus on polyketides. Kosan’s technology permits modifications of polyketides not feasible by chemical methods, greatly expanding the repertoire of polyketides. Therapeutic targets for the Company’s compounds include infectious diseases, gastrointestinal motility disorders, respiratory inflammation, cancer, nerve regeneration and immunosuppression.
For further information :
Daniel V. Santi, M.D., Ph.D. CEO and President KOSAN Biosciences, Inc. 3832 Bay Center Pl. Hayward, CA 94545 www.kosan.com Tel: 510-732-8400 ext. 204 Fax: 510-732-8401
Andrew Lloyd & Associates 95 Ditchling Road Brighton BN1 4ST +44-1273 675100 – Andrew Lloyd email : firstname.lastname@example.org
Allschwil. Actelion Ltd. today announced that it has begun its international
Phase III clinical development program on tezosentan for intravenous use in
patients with acute heart failure.
Tezosentan is the first endothelin receptor antagonist optimized for the
treatment of acute pathological conditions. It has a rapid onset of action and a
short half-life allowing an easy titration. The results of the US Phase II
clinical trials will be presented at the American Heart Association Meeting in
Atlanta early November.
“Our goal is to establish tezosentan as the major emergency drug for the
treatment of acute heart failure, » commented Martine Clozel, Vice-President at
Actelion and discoverer of tezosentan. « We believe that tezosentan may have
substantial benefits over existing therapy. »
Acute heart failure is a clinical entity resulting from an acute failure of
the cardiac pump to meet the needs of peripheral metabolism. It is the number
one cause of hospitalization in the elderly. In the US alone, more than 1.5
million patients are hospitalized per year for acute heart failure.
Located in Allschwil, Switzerland, Actelion Ltd. is an emerging
pharmaceutical company aiming to bring to the market innovative proprietary
drugs through creative science related to the endothelium. Founded in December
1997, Actelion Ltd. is backed by leading international venture capital and
private investment funds.
Contact person for Actelion: Dr. Peter
Herrmann, Vice President, Head of Drug Registration and Communication Phone: +41
61 487 45 39, E-mail email@example.com